- Previous Close
1.9800 - Open
1.8900 - Bid 1.8700 x 200
- Ask 1.9300 x 200
- Day's Range
1.7500 - 1.9400 - 52 Week Range
1.4100 - 7.8400 - Volume
496,171 - Avg. Volume
226,919 - Market Cap (intraday)
16.691M - Beta (5Y Monthly) 2.08
- PE Ratio (TTM)
-- - EPS (TTM)
-2.2300 - Earnings Date Feb 25, 2025 - Mar 3, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
9.50
Lifeward Ltd., a medical device company, designs, develops, and commercializes technologies that enable mobility and wellness in rehabilitation and daily life for individuals with physical and neurological conditions in the United States, Europe, the Asia-Pacific, and internationally. It offers ReWalk personal exoskeleton and rehabilitation exoskeleton devices; ReStore, a soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke; AlterG Anti-Gravity System for use in physical and neurological rehabilitation and athletic training; MyoCycle devices; and ReBoot, a personal soft exo-suit for home and community use by individuals post-stroke. The company markets and sells its products directly to institutions and individuals, as well as through third-party distributors. The company was formerly known as ReWalk Robotics Ltd. and changed its name to Lifeward Ltd. in September 2024. Lifeward Ltd. was incorporated in 2001 and is headquartered in Yokneam Illit, Israel.
golifeward.comRecent News: LFWD
View MorePerformance Overview: LFWD
Trailing total returns as of 1/10/2025, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: LFWD
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: LFWD
View MoreValuation Measures
Market Cap
16.69M
Enterprise Value
7.02M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.66
Price/Book (mrq)
0.49
Enterprise Value/Revenue
0.28
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-102.03%
Return on Assets (ttm)
-23.73%
Return on Equity (ttm)
-49.65%
Revenue (ttm)
23.28M
Net Income Avi to Common (ttm)
-23.75M
Diluted EPS (ttm)
-2.2300
Balance Sheet and Cash Flow
Total Cash (mrq)
15.13M
Total Debt/Equity (mrq)
3.52%
Levered Free Cash Flow (ttm)
-13.66M